GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (TSXV:IPCI) » Definitions » EV-to-Revenue

IntelliPharmaCeutics International (TSXV:IPCI) EV-to-Revenue : 4.20 (As of May. 01, 2024)


View and export this data going back to 1999. Start your Free Trial

What is IntelliPharmaCeutics International EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, IntelliPharmaCeutics International's enterprise value is C$5.13 Mil. IntelliPharmaCeutics International's Revenue for the trailing twelve months (TTM) ended in Aug. 2023 was C$1.22 Mil. Therefore, IntelliPharmaCeutics International's EV-to-Revenue for today is 4.20.

The historical rank and industry rank for IntelliPharmaCeutics International's EV-to-Revenue or its related term are showing as below:

TSXV:IPCI' s EV-to-Revenue Range Over the Past 10 Years
Min: -1.97   Med: 9.59   Max: 678.58
Current: 4.2

During the past 13 years, the highest EV-to-Revenue of IntelliPharmaCeutics International was 678.58. The lowest was -1.97. And the median was 9.59.

TSXV:IPCI's EV-to-Revenue is ranked better than
64.12% of 1034 companies
in the Biotechnology industry
Industry Median: 7.775 vs TSXV:IPCI: 4.20

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-01), IntelliPharmaCeutics International's stock price is C$0.08. IntelliPharmaCeutics International's Revenue per Share for the trailing twelve months (TTM) ended in Aug. 2023 was C$0.04. Therefore, IntelliPharmaCeutics International's PS Ratio for today is 2.16.


IntelliPharmaCeutics International EV-to-Revenue Historical Data

The historical data trend for IntelliPharmaCeutics International's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International EV-to-Revenue Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.80 1.49 3.43 - 71.08

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.04 71.08 10.87 4.60 4.58

Competitive Comparison of IntelliPharmaCeutics International's EV-to-Revenue

For the Biotechnology subindustry, IntelliPharmaCeutics International's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's EV-to-Revenue falls into.



IntelliPharmaCeutics International EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

IntelliPharmaCeutics International's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=5.132/1.221
=4.20

IntelliPharmaCeutics International's current Enterprise Value is C$5.13 Mil.
IntelliPharmaCeutics International's Revenue for the trailing twelve months (TTM) ended in Aug. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IntelliPharmaCeutics International  (TSXV:IPCI) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

IntelliPharmaCeutics International's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.08/0.037
=2.16

IntelliPharmaCeutics International's share price for today is C$0.08.
IntelliPharmaCeutics International's Revenue per Share for the trailing twelve months (TTM) ended in Aug. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.04.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IntelliPharmaCeutics International EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (TSXV:IPCI) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (TSXV:IPCI) Headlines

No Headlines